What's the Problem?
Throughout the world, there is a constant increase in the number of patients who, due to various pathologies, have a critical need for organ transplants. However, the number of organs available, whether from living or deceased donors, is very limited. This generates long waiting lists, which continue to grow each year. In 2018, according to the WHO, only 15% of the organ demand was covered, leaving more than 800,000 people waiting around the world. Even though in many countries there have been changes in the legislation in favor of organ donation, the gap between organ supply and demand continues to widen and the problem remains unsolved.
How are they Solving it?
Transplantation of animal organs, such as pigs to humans, known as xenotransplantation, is the most feasible alternative to respond to this growing unmet demand for organs. But the incompatibility generates hyperacute immune rejection. NewOrgans Biotech can produce human compatible pigs. These pigs must carry certain modifications in their genome to avoid immune rejection in human patients. The latest gene editing technologies (CRISPR/Cas) and transposons, as well as the knowledge of pig and human genomes, will allow New Organs Biotech to achieve this goal.